BioWorld MedTech

March 26, 2013

Deals roundup: Argon to acquire Angiotech interventional unit for $362M

In a move to perhaps eliminate a significant portion of its debt, Angiotech Pharmaceuticals (Vancouver, British Columbia) reported the sale of its interventional products business to Argon Medical Devices (Plano, Texas) for $362.5 million. Read More

Third Rock raises $516M in oversubscribed Fund III

Financings roundup: Bausch + Lomb files IPO registration statement

Washington roundup: FDA warning to Stryker offers no insight into Neptune recall

International report: Stereotaxis receives regulatory approval of Niobe tech in Japan

Agreements/contracts: Aerocrine, Medisoft agree to licensing settlement terms

Court report: BCBSM files motion to dismiss antitrust lawsuit filed against it

Grants roundup: Stanford pediatric cancer study receives funding

Med-Tech Notes

Product Briefs

People in the News

MDD's Cardio Extra

Today's news in brief

BioWorld

BioWorld briefs for Jan 15, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 15, 2026.

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

LINC01116 has prognostic value in lung cancer, study shows

BioWorld MedTech

Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...

SERPINB1 as potential biomarker for spinocerebellar ataxia type 2

BioWorld Science

Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...